GSA Capital Partners LLP Sells 231,696 Shares of Savara Inc. $SVRA

GSA Capital Partners LLP decreased its position in Savara Inc. (NASDAQ:SVRA) by 62.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,753 shares of the company’s stock after selling 231,696 shares during the quarter. GSA Capital Partners LLP’s holdings in Savara were worth $849,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Savara by 9.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock worth $200,000 after acquiring an additional 2,859 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after acquiring an additional 3,205 shares in the last quarter. BNP Paribas Financial Markets grew its position in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares during the period. The Manufacturers Life Insurance Company grew its position in Savara by 14.2% during the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after buying an additional 6,449 shares during the period. Finally, ProShare Advisors LLC grew its position in Savara by 35.5% during the fourth quarter. ProShare Advisors LLC now owns 34,869 shares of the company’s stock valued at $210,000 after buying an additional 9,133 shares during the period. Institutional investors own 87.93% of the company’s stock.

Savara Price Performance

SVRA opened at $5.02 on Friday. The firm has a market cap of $1.03 billion, a P/E ratio of -8.96 and a beta of 0.28. The firm has a 50-day moving average of $5.30 and a 200 day moving average of $5.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $7.01.

Savara (NASDAQ:SVRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, research analysts expect that Savara Inc. will post -0.58 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SVRA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Oppenheimer started coverage on shares of Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. William Blair set a $10.00 price target on shares of Savara in a research report on Monday, March 16th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Finally, HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.13.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.